ANNUAL REPORT 2021

LUNDBECK ANNUAL REPORT 2021 = CONTENTS CONSOLIDATED FINANCIAL STATEMENTS NOTES 1-2 57/111 1 BASIS OF PREPARATION - CONTINUED 1.7 New standards and amendments issued but not yet effective A number of new standards and amendments are effective for annual periods beginning after 1 January 2021 though not mandatory for annual reporting periods ending on 31 December 2021. Earlier application is permitted; however, the new or amended standards have not been early adopted by the Group. The amended standards are as follows: • A number of narrow-scope amendments to IFRS 3 Business Combinations, IAS 16 Property, Plant and Equipment, IAS 37 Provisions, Contingent Liabilities and Contingent Assets and some annual improvements on IFRS 1 First-time Adoption of International Financial Reporting Standards, IFRS 9 Financial Instruments and IFRS 16 Leases • Classification of liabilities as current or non-current (Amendments to IAS 1 Presentation of Financial Statements) • Disclosure of Accounting Policies (Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2) • Definition of Accounting Estimate (Amendments to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors) • Amendment to IAS 12 Income taxes - deferred tax related to assets and liabilities arising from a single transaction. The Group expects to adopt the new standards, improvements, amendments and interpretations when they become mandatory. None of the amended standards are expected to have significant impact on the accounting policies and/or on the consolidated financial statements. 1.8 European Single Electronic Format (ESEF) The Annual Report is prepared in XHTML format, and the consolidated financial statements are tagged using inline extensible Business Reporting Language (iXBRL). The iXBRL tags comply with the ESEF taxonomy, which is included in the ESEF Regulation and developed based on the IFRS taxonomy published by the IFRS Foundation. Where a financial statement line item is not defined in the ESEF taxonomy, an extension to the taxonomy has been created. Extensions are anchored to elements in the ESEF taxonomy, except for extensions which are subtotals. The Annual Report submitted to the Danish Financial Supervisory Authority consists of the XHTML document together with certain technical files, all included in a ZIP file named HLUNDBECK-2021-12-31-en.zip. 2 REVENUE AND SEGMENT INFORMATION The Group is engaged in research, development, production and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders, which is the Group's single business (operating) segment. The business segment reflects the way in which Management makes decisions and assesses the business performance. The Group is organized in geographical regions. The tables below show the Group's revenue from external customers broken down by key products and geographical regions. 2021 Abilify MaintenaⓇ BrintellixⓇ/Trintellix® Cipralex /LexaproⓇ NortheraⓇ Onfi® RexultiⓇ/RxultiⓇ SabrilⓇ VyeptiⓇ Other pharmaceuticals Revenue by product Other revenue Effects from hedging Total revenue Of this amount: Royalty Down payments and milestone received Europe North America International DKKm DKKm Markets DKKM Group DKKm 1,175 1,019 226 2,420 998 1,789 739 3,526 530 117 1,699 2,346 665 665 505 505 25 2,725 99 2,849 657 657 489 492 771 279 1,389 2,439 3,499 8,245 4,155 15,899 347 53 16,299 775 13

View entire presentation